Funding led by TK Partners supports further clinical validation, regulatory preparation, and commercialization of OncoGaze™

TK Partners领投的资金支持OncoGaze™的进一步临床验证、监管准备和商业化。

SAN DIEGO

圣地亚哥

,

，

April 2, 2026

2026年4月2日

/PRNewswire/ -- Acurion, a precision oncology technology company advancing AI-driven cancer biomarker detection through its OncoGaze™ platform, today announced the closing of its oversubscribed seed financing round, raising $4.3 million against a $4 million target.

/PRNewswire/ -- Acurion是一家通过其OncoGaze™平台推动人工智能驱动的癌症生物标志物检测的精准肿瘤技术公司，今天宣布其超额认购的种子轮融资结束，成功筹集了430万美元，超过了原定400万美元的目标。

The round was led by TK & Partners, with participation from Mesa Verde Venture Partners, The National Foundation for Cancer Research and the Asian Fund for Cancer Research, Bootstrap Ventures, and institutional investors, impact funds, and healthcare executives.

本轮融资由TK & Partners领投，Mesa Verde Venture Partners、美国国家癌症研究基金会、亚洲癌症研究基金会、Bootstrap Ventures以及机构投资者、影响力基金和医疗保健高管参与。

The financing will further support clinical validation, platform development, regulatory preparation, and commercialization as Acurion advances OncoGaze™ toward broader clinical and research adoption.

这笔资金将为进一步的临床验证、平台开发、监管准备和商业化提供支持，因为Acurion正在推动OncoGaze™走向更广泛的临床和研究应用。

'This financing represents strong validation of our technology and mission,' said Rick Fultz, CEO of Acurion. 'The future of precision oncology depends on making advanced biomarker detection accessible, scalable, and instantly actionable in real-world clinical settings. This investment helps us accelerate development and bring our technology closer to meaningful impact for cancer patients.'  .

“这笔融资代表了对我们技术和使命的强烈认可，”Acurion首席执行官Rick Fultz表示。“精准肿瘤学的未来取决于在现实临床环境中使先进的生物标志物检测变得可及、可扩展且即时可行。这项投资有助于我们加速开发，并使我们的技术更接近为癌症患者带来有意义的影响。”

'Acurion stood out immediately — tackling a global problem with a strong technical edge, a standout team, and a clear approach to execution,' said TK & Partners' Chairman, Tomas Koch.

“阿库里恩立刻脱颖而出——凭借强大的技术优势、出色的团队和清晰的执行方法来解决一个全球性问题，”TK & Partners董事长托马斯·科赫表示。

'AI has the potential to reshape how we detect and act on cancer biomarkers,' said Carey Ng, Ph.D., Managing Partner at Mesa Verde Venture Partners. 'What stood out to us about Acurion is their ability to translate complex science into a solution that fits directly into existing clinical workflows. This is the kind of innovation that can expand access to precision oncology at scale.'  .

“人工智能有潜力重塑我们检测和应对癌症生物标志物的方式，”Mesa Verde Venture Partners的管理合伙人Carey Ng博士说道。“Acurion让我们眼前一亮的是他们能够将复杂的科学转化为直接融入现有临床工作流程的解决方案。这种创新可以大规模扩展精准肿瘤学的可及性。”

Acurion's technology builds on foundational work by co-founder and Chief Scientific Officer Ludmil Alexandrov, Ph.D., Professor of Cellular and Molecular Medicine at UC San Diego, whose work on mutational signatures has reshaped understanding of cancer origins and treatment response.

Acurion的技术建立在联合创始人兼首席科学官Ludmil Alexandrov博士的基础工作之上，他是加州大学圣地亚哥分校细胞与分子医学教授，其在突变特征方面的研究重塑了对癌症起源和治疗反应的理解。

The company has achieved significant scientific and industry milestones, including publications in leading oncology and scientific journals, expanding collaborations with clinical partners, and engaging industry leaders.

公司已经取得了重要的科学和行业里程碑，包括在领先的肿瘤学和科学期刊上发表文章、扩大与临床合作伙伴的合作以及吸引行业领袖的参与。

'We're moving quickly from validation to deployment,' Fultz added. 'Our focus now is executing key clinical and regulatory milestones and getting this into the hands of physicians who can use it.'

“我们正在迅速从验证阶段转向部署阶段，”福尔茨补充道。“我们现在的工作重点是执行关键的临床和监管里程碑，并将其交到能够使用的医生手中。”

The company expects to announce additional clinical collaborations and regulatory progress in the coming months.

公司预计将在未来几个月内宣布更多的临床合作和监管进展。

About Acurion

关于Acurion

Acurion is a San Diego-based precision oncology company developing AI-powered image analysis tools for biomarker detection, uncovering clinically actionable insights from conventional pathology images. Unlike genomic testing approaches often requiring additional tissue or specialized molecular testing, Acurion's OncoGaze™ platform extracts biomarker insights from routine pathology slides prepared during standard clinical care, enabling an instantaneous, scalable and accessible approach to precision medicine.

Acurion是一家位于圣地亚哥的精准肿瘤学公司，致力于开发基于人工智能的图像分析工具，用于生物标志物检测，并从常规病理图像中挖掘出具有临床操作价值的信息。与通常需要额外组织或专门分子测试的基因组检测方法不同，Acurion的OncoGaze™平台能够从标准临床护理期间制备的常规病理切片中提取生物标志物信息，从而实现即时、可扩展且易于获取的精准医疗方法。

.

。

Despite major advances in targeted therapies, many cancer patients either lack access to biomarker testing or face life-threatening testing delays. Acurion aims to expand access to precision oncology by improving biomarker detection and treatment selection across multiple advanced cancer types.

尽管靶向治疗取得了重大进展，但许多癌症患者要么无法获得生物标志物检测，要么面临危及生命的检测延误。Acurion 旨在通过改进多种晚期癌症类型的生物标志物检测和治疗选择，扩大精准肿瘤学的可及性。

For more information visit:

欲了解更多信息，请访问：

www.acurionhealth.com

www.acurionhealth.com

Media Contact

媒体联系人

Catherine Eng

凯瑟琳·Eng

[email protected]

电子邮件地址

818-795-7184

818-795-7184

SOURCE Acurion

来源 Acurion

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示